• By ICR Secretariat
  • Posted Wednesday, April 22, 2020

Gilead's remdesivir looks promising in leaked early results, but don't jump to conclusions: analysts

https://www.fiercebiotech.com/biotech/gilead-stock-jumps-after-report-reveals-early-data-for-remdesivir-trial

The world is watching and waiting for data to see whether Gilead Sciences' investigational antiviral remdesivir can help fight COVID-19. And while some leaked early results suggest that it can, industry watchers will need to wait for data from Gilead's own controlled phase 3 study to know for sure.

Researchers at the University of Chicago Medical Center, which is treating patients with severe COVID-19, have seen remdesivir swiftly tamp down both fever and respiratory symptoms, according to a report from Stat. Gilead’s shares leapt more than 15% in after-hours trading following the report.